Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered VO659 in Participants With Spinocerebellar Ataxia Types 1, 3 and Huntington's Disease

NCT05822908 is registered in ClinicalTrials.gov with Vico Therapeutics B. V. as lead sponsor.

NCT NCT05822908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05822908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered VO659 in Participants With Spinocerebellar Ataxia Types 1, 3 and Huntington's Disease
Lead sponsor
Vico Therapeutics B. V.
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 14, 2023
Completion date
October 15, 2028
Enrollment
68 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

huntington disease, spinocerebellar ataxia type 1, spinocerebellar ataxia type 3